Pipeline
Overview
Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.
Pipeline
Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.
Our world-leading drug discovery and development platform gives us the opportunity to explore multiple additional DUB targets of relevance to other disease indications, both in-house and through partnerships with other pharmaceutical companies.
Several of our USP30 inhibitor programs are now approaching clinical development.
Research | Preclinical | Phase I |
---|
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Acute Kidney Injury
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Idiopathic Pulmonary Fibrosis
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Familial Parkinson’s Disease / Mitochondrial Disease
DUB program: DUB X
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed
Research | Preclinical | Phase I |
---|
DUB program: AbbVie collaboration
Rationale/target: Undisclosed
Therapeutic indication: Alzheimer’s and Parkinson’s
Development stage: Undisclosed
DUB program: Pfizer collaboration
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed
Development stage: Undisclosed